BMS’ CAR-T Therapy Shows Promising Results in Treating Lupus, Achieving Sustained Responses in Phase 1 Trial

CAR T therapy, Lupus treatment, Bristol Myers Squibb (BMS), Systemic lupus erythematosus (SLE), Autoimmune diseases, Cell therapy, Clinical trials

FDA Mandates Enhanced Safety Warnings for CAR-T Therapies Due to Secondary Cancer Risks

CAR-T therapy, secondary cancers, FDA boxed warnings, T-cell malignancies, BCMA-directed, CD19-directed, autologous CAR T-cell immunotherapies.